← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Lynthera Corporation
Lancaster, PA
$6,523,712
Total funding
8
Grants
Funding over time
peak $1.8M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,298,712 · 7
NSF$225,000 · 1
By mechanism
R44$5,067,962 · 3
R43$1,230,750 · 4
—$225,000 · 1
Investigators at Lynthera Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Drug delivery platform for ocular allergy therapy$900,003
R44 · FY2024 · EY
Drug delivery platform for ocular allergy therapy$900,003
R44 · FY2025 · EY
Sustained delivery technology for Cyclosporine A in the treatment of autoimmune response$795,000
R44 · FY2023 · EY
Sustained delivery technology for Cyclosporine A in the treatment of autoimmune response$795,000
R44 · FY2024 · EY
Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$754,785
R44 · FY2018 · EY
Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$754,259
R44 · FY2019 · EY
Novel formulation technology for the sustained release naloxone to improve outcomes in the management of opioid overdose$320,000
R43 · FY2023 · DA
Drug delivery platform for ocular allergy therapy$300,000
R43 · FY2022 · EY
Sustained delivery technology for Cyclosporine A in the treatment of autoimmune response$300,000
R43 · FY2021 · EY
Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$225,000
R43 · FY2016 · EY
SBIR Phase I: Contact lens with innovative nanoparticles for multi-week, controlled delivery of glaucoma drugs$225,000
· FY2016 · TIP
Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$168,912
R44 · FY2020 · EY
I-Corps for Novel Formulation Technology for Sustained Release Naloxone$55,000
R43 · FY2024 · DA
Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$30,750
R43 · FY2016 · EY